PeptideStack
5.2kquestions
20kanswers
220users

Would you re-test oral semaglutide after ten weeks at minus 80 °C, or accept the original certificate?

Asked 14 Apr 2024Modified 2.0 years agoViewed 24k times
17

For reference: oral semaglutide · ten weeks · minus 80 °C.

I would like to define my thresholds before I have a result, for obvious reasons.

I want a plan with explicit stopping rules, not just steps.

What does a sensible plan look like, and what are the decision points?

batch-testing
batch-testing

Testing at the batch or lot level: sampling plans, how many vials from a lot need testing to say anything about the lot, and the difference…

865 questions
peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

832 questions
coa
coa

Certificates of analysis: what fields a useful one carries, how to tell a real analytical report from a marketing document, batch and lot…

749 questions
shareeditfollowflag
NK
askednils_karlberg13k1714 Apr 2024
3The timing signature is the useful part. Everything else is confounded. – tess_amankwah 5 months ago
add a comment

5 Answers

Accepted answer first, then by votes
77

Accepted answer

Sampling plans exist precisely because testing everything is expensive, and they define the statistical relationship between sample size and lot-wide inference.

Acceptance Sampling by Attributes defines the number of samples you need from a lot to claim a specified quality level at a specified risk — it is in ANSI standard Z1.4.

What each test answers

TestAnswersDoes NOT answer
RP-HPLC, area %What fraction of detected material is the targetHow much target is present
Quantified contentMilligrams of peptide per vialWhat the impurities are
ESI-MS identityWhether the molecular weight matchesPurity, or isomeric substitution
Peptide mappingSequence, localised to a fragmentQuantity
Karl FischerWater content of the solidSolvent content
LAL endotoxinPyrogen load in EU/mgSterility
Sterility testGrowth in defined media over 14 daysEndotoxin, or bioburden count

The part that matters: stratified sampling — testing one vial from the top, one from the middle, and one from the bottom of a shipment — is cheap insurance against segregation.

Lyophilised peptide homogeneity studies show that vial-to-vial variation is usually small but occasionally large, depending on the distribution in the freeze-dryer.

The practical summary: a lot number without a sampling statement is a lot number without meaning.

shareimprove this answerflag
GS
answered · acceptedgradient_slope41k3817 Jun 2024
Sponsored

Sigma-Aldrich - Certified Reference Materials

Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.

Shop standards
31

In practice, start from the question: how many vials from this lot do I need to test to claim that the lot meets specification, and the answer depends on both the lot size and the acceptable risk.

Under AQL sampling plans, testing two vials from a fifty-vial lot gives you an operating characteristic curve that tells you what risks you are accepting.

For a quantitative result like content, the acceptable range determines how many vials you need to test to establish the lot complies.

Published data on lot homogeneity from manufacturers who sample multiple vials consistently find variation below the published specifications, suggesting the sampling plans work.

I would treat a "complies with" statement without sampling details as a claim rather than as evidence.

Assume segregation is possible, and design your sampling to catch it if it exists.

edited 4 Jul 2024 by nkem_obiora — added the method parameters

shareimprove this answerflag
NO
answerednkem_obiora46k386 Jun 2024
2Small correction: the units in the third paragraph should be micrograms, not milligrams. – lucia_marchetti 9 months ago
3Do you have a reference for the last claim? Not disputing it, just want to read it. – tabular_nums 18 days ago
add a comment
21

Specifically, most suppliers test one vial per lot and report the result as lot homogeneity, which is sampling one item from one lot and extrapolating wildly.

If you have reason to suspect inhomogeneity — different appearance in different vials, or a long or warm shipment — testing more vials is the diagnostic move.

If the lot was manufactured in multiple batches, testing vials from each batch separately establishes whether batch-to-batch variation is acceptable.

If testing multiple vials, state how many you tested and why you chose those vials.

shareimprove this answerflag
DH
answeredDr_Wren_Halliday40k3826 May 2024
7The timing signature is the useful part. Everything else is confounded. – w_okoye 10 months ago
add a comment
18

The part that matters: the failure mode here is publishing a result that applies to the tested vial alone while implying it applies to the entire lot.

A statement that "lot 20260412 complies with specifications" is meaningless without stating which vials from the lot were tested and how many there were.

Sampling plans for pharmaceutical manufacturing are defined in ISO 2859 and ANSI Z1.4, and they are based on statistical sampling theory.

The practical summary: a lot number without a sampling statement is a lot number without meaning.

shareimprove this answerflag
WC
answeredwren_calloway14k1815 May 2024
5Confirming from the other direction: I did the wrong thing and got exactly the predicted outcome. – seven_day_half 4 months ago
6Is there a reason to prefer the second method over the first, other than cost? – ilaria_bertone 6 months ago
add a comment
13

The underlying point is that batch testing establishes what can be claimed about the lot as a whole, and the sample size determines how much you can actually claim.

The statistical foundation here is well-established, which is why sampling plans from decades ago are still valid.

Assume segregation is possible, and design your sampling to catch it if it exists.

shareimprove this answerflag
MS
answeredmarta_szymanska17k381 Aug 2024
8The timing signature is the useful part. Everything else is confounded. – vialroom 9 months ago
add a comment

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.